Glenmark pharmaceuticals limited, Company

Share India Securities Limited, one of India's leading hi- tech broking Company and financial service provider, announced strong financial results for the quarter and year ended March 31st 2020.Share India Securities Limited is a key player in derivative market segment with ~5 per cent share of derivative turnover in NSE F&O. With a consolidated total revenue of Rs 2793.46 Mn in FY 20, Share India, amongst the listed broking compes, became the 4th largest broking company in terms of revenue from operations albeit with a much smaller physical footprint due to its focus on technology and customized products for its clients.Powered with 1300 employees, the company has been in operation since last 26 years and has a nationwide reach with its 587 plus branches present across 14 major states of India.HIGHLIGHTS OF CONSOLIDATED Y-o-Y RESULTS:The Company's consolidated net profit after tax (PAT) for the year ended March 31, 2020 increased substantially by 60 per cent to Rs 400.01 Mn vs. Rs 249.93 Mn in the previous FY 2019. The consolidated total revenues grew significantly to Rs 2,793.46 Mn from Rs 2,071.86 Mn in FY 19, registering an increase of 34.83 per cent. The Basic EPS stood to Rs 12.54 (grew 60.15 per cent YoY). As on July 17, 2020, the Market Capitalization of the Company stands at Rs 277.75 crores.CONSOLIDATED Q4 - 20 (Y-o-Y) and (Q-o-Q):For the quarter ended March 31, 2020, the company's consolidated total revenue increased to Rs 1,056.12 Mn, resulting in growth of 80.81 per cent Y-o-Y basis and 62.48 per cent Q-o-Q basis. Consolidated net profit after tax for the quarter jumped to Rs 169.92 Mn, resulting in growth of 215.43 per cent Y-o-Y basis and 67.96 per cent Q-o-Q basis.BUSINESS HIGHLIGHTSIn FY 20, the Company merged 'Total Securities Limited', a leading Mumbai-based Stock Broking Co in an all equity deal, which led Share India towards strengthening of its financial position, enhancement in leadership and increase in geographical presence.The Company added 80 new branches in FY 20, leading to total count of 587 branches/franchises. The Company was also successful in expanding its operations in NBFC and Mutual fund distribution as well* NBFC Business:* Loan book size increased by 104 per cent to Rs 616 Mn as compared to Rs 301 Mn in FY 19;* Net Interest Income increased by 212 per cent to Rs 40.3 Mn as compared to Rs 12.9 Mn in FY 19,* Wealth Management:* AuM of Mutual Funds increased by Rs 170 Mn to Rs 1129 Mn"Over the times, we have grown from a traditional stock broker to now a hi-tech broking Company leveraging on tech leadership, algorithmic trading and consistently providing customized capital market tech-based solutions to our clients. In alignment to our vision to be a complete financial service provider, we expanded our operations this year in the NBFC business, insurance broking, merchant banking and mutual funds distribution as well. In upcoming times, we expect to grow multifold and have strong foothold in being a complete financial service provider. Most of our strategy for product expansion in multiple avenues of capital markets is now complete and our focus is to increase the size and scale of these businesses in coming years Our dynamic business strategies focused on strong growth have led us to reach at record levels in FY 20. We are proud of our growing track record and financial performance during FY 20, and moving forward we have geared ourselves to meet our client needs effectively even in this COVID-19 crisis," said Sachin Gupta, CEO and Whole Time Director, Share India, while commenting on the successful results."We would like to assure our stockholders that our underlying fundamentals remain firmly intact, due to strong handhold across our business segments. While the immediate short-term will be challenging, looking ahead, we can see that there is a strong interest to grow our Insurance business. I am confident that we will emerge from this stronger," said Kamlesh Vadilal Shah, Managing Director, Share India.This story is provided by PRNewswire. will not be responsible in any way for the content of this article. (/PRNewswire)( With inputs from ANI )

Glenmark Pharmaceuticals LimitedFOLLOW

Glenmark pharmaceuticals limited, Latest News

Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the third quarter ended December 31 of the financial year 2020-21. ...

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food and Drug Administration (U.S. FDA) for Clindamycin Phosphate Gel USP, 1 per cent, the generic version of Cleocin T® Gel, 1 per cent, of Pharmacia and Up ...

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, the generic version of Qudexy®1 XR ...

Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the third quarter ended December 31, 2020 (Q3FY21). ...

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg, the generic version of Evekeo®1 Tablets, 5 mg and 10 mg, of Arbor ...

Highlights for Q1 FY 2020-21 ...

TVS Motor Company registered a sales growth of 27 per cent in July 2020 with 252,744 units as against 198,387 units in June 2020. ...

Share India Securities Limited, one of India's leading hi- tech broking Company and financial service provider, announced strong financial results for the quarter and year ended March 31st 2020. ...